Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease

Maria Pérez Marín; Laurent Arthur Decosterd; Pascal Andre; Thierry Buclin; Thomas Mercier; Kristina Murray; Mattia Rizzi; Pascal Meylan; Katia Jaton-Ogay; Onya Opota; Carole Gengler; Marie-Hélène Perez; Julia Natterer; Sandra Andrea Asner

doi:10.1093/jpids/piz033

Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease

J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):96-99. doi: 10.1093/jpids/piz033.

Authors

Affiliations

¹ Pediatric Intensive Care Unit, University Hospital Center and University of Lausanne, Switzerland.
² Service of Clinical Pharmacology, University Hospital Center and University of Lausanne, Switzerland.
³ Pediatric Infectious Diseases and Vaccinology Unit, Woman-Mother-Child Department, University Hospital Center and University of Lausanne, Switzerland.
⁴ Pediatric Hematology-Oncology Unit, University Hospital Center and University of Lausanne, Switzerland.
⁵ Institute of Microbiology, Department of Laboratories, University Hospital Center and University of Lausanne, Switzerland.
⁶ Department of Pathology, University Hospital Center and University of Lausanne, Switzerland.
⁷ Infectious Diseases Service, Department of Medicine, University Hospital Center and University of Lausanne, Switzerland.

PMID: 31183500
DOI: 10.1093/jpids/piz033

Abstract

Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.

Keywords: cytomegalovirus disease; cytomegalovirus infection; letermovir; therapeutic drug monitoring.

© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Publication types

Case Reports

MeSH terms

Acetates / administration & dosage*
Acetates / pharmacokinetics
Acetates / therapeutic use
Antiviral Agents / administration & dosage*
Antiviral Agents / pharmacokinetics
Antiviral Agents / therapeutic use
Child, Preschool
Compassionate Use Trials
Cytomegalovirus Infections / drug therapy*
Cytomegalovirus Infections / immunology
Cytomegalovirus Infections / virology
Cytomegalovirus* / genetics
Cytomegalovirus* / isolation & purification
DNA, Viral / blood
Dose-Response Relationship, Drug
Drug Monitoring / methods*
Extracorporeal Membrane Oxygenation / adverse effects
Fatal Outcome
Female
Ganciclovir / therapeutic use
Hepatitis, Viral, Human / drug therapy
Hepatitis, Viral, Human / immunology
Humans
Immunocompromised Host*
Opportunistic Infections / drug therapy
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
Polymerase Chain Reaction
Quinazolines / administration & dosage*
Quinazolines / pharmacokinetics
Quinazolines / therapeutic use
Treatment Failure
Viral Load

Substances

Acetates
Antiviral Agents
DNA, Viral
Quinazolines
letermovir
Ganciclovir